Jump to content

Wikipedia:Choosing Wisely/American Society of Clinical Oncology: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
→Articles of interest: another term...
ce
 
(43 intermediate revisions by 8 users not shown)
Line 1: Line 1:
This project shares information from the American Society of Clinical Oncology on Wikipedia.
This project shares information from the [[American Society of Clinical Oncology]] on Wikipedia.


==Articles of interest==
==Articles of interest==
Line 5: Line 5:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
! colspan="7" style="background-color: #CCEEEE;" | Articles relating to AAAAI content
! colspan="4" style="background-color: #CCEEEE;" | Articles relating to American Society of Clinical Oncology content
|-
|-
! article
! article
! traffic
! traffic in April 2014*
! pageview count*
! pageview date*
! example change
! sources cited
! sources cited
! change summary
! change summary
|-
|-
| [[American Society of Clinical Oncology]]
| [[American Society of Clinical Oncology]]
| [http://stats.grok.se/en/latest/American_Society_of_Clinical_Oncology chart]
| [http://stats.grok.se/en/201404/American_Society_of_Clinical_Oncology 1137]
|
| align=right | 579
| 03 Aug 12
|
|
|
|
|-
|-
| [[Bone scintigraphy]]
| [[Breast cancer]]
| [http://stats.grok.se/en/latest/Bone_scintigraphy chart]
| [http://stats.grok.se/en/201404/Breast_cancer 66939]
|
| align=right | 10558
| [http://en.wikipedia.org/enwiki/w/index.php?title=Breast_cancer&diff=525192523&oldid=525094233 history]
| 15 Nov 12
|
|-
| [[Breast cancer treatment]]
|
| [http://stats.grok.se/en/201404/Breast_cancer_treatment 605]
|
| 3
| [http://en.wikipedia.org/enwiki/w/index.php?title=Breast_cancer_treatment&diff=525191471&oldid=523283585 recommend against a physician's use of PET scans, CT scans, or bone scans when staging early breast cancer with low risk for metastasis]
|-
|-
| [[Cancer]]
| [[Cancer]]
| [http://stats.grok.se/en/latest/Cancer chart]
| [http://stats.grok.se/en/201404/Cancer 138119]
| 1
| align=right | 214257
| [http://en.wikipedia.org/enwiki/w/index.php?title=Cancer&diff=523337873&oldid=523333447 In some cases, medical specialty professional organizations recommend that patients and physicians respond to cancer only with palliative care and not with cancer-directed therapy]
| 15 Nov 12
|-
| [http://en.wikipedia.org/enwiki/w/index.php?title=Cancer&diff=523337873&oldid=523333447 history]
| [[Cancer staging]]
| <ref name="ASCOfive"/><ref name="2011lungcancer"/><ref name="EttingerLungCancer"/><ref name="CarlsonBreast"/><ref name="EngstromColon"/><ref name="SmithHillner"/><ref name="PeppercornSmith"/><ref name="MakarovDesai"/>
| [http://stats.grok.se/en/201404/Cancer_staging 25644]
| added fundamental information on when not to provide cancer-directed therapy in favor of only palliative care
| 2, 3
| [http://en.wikipedia.org/enwiki/w/index.php?title=Cancer_staging&diff=525197271&oldid=524623781 recommend against the use of PET scans, CT scans, or bone scans because research shows that the risk of getting such procedures outweighs the possible benefits]
|-
| [[Palliative care]]
| [http://stats.grok.se/en/201404/Palliative_care 61724]
| 1
| [http://en.wikipedia.org/enwiki/w/index.php?title=Palliative_care&diff=524970504&oldid=522518694 In some cases, medical specialty professional organizations recommend that patients and physicians respond to cancer only with palliative care and not with cancer-directed therapy]
|-
| [[Prostate cancer]]
| [http://stats.grok.se/en/201404/Prostate_cancer 64413]
|
|
|-
|-
| [[Chemotherapy]]
| [[Chemotherapy]]
| [http://stats.grok.se/en/latest/Chemotherapy chart]
| [http://stats.grok.se/en/201404/Chemotherapy 71985]
|
| align=right | 118346
|
| 15 Nov 12
|
|
|
|-
|-
| [[Clinical trial]]
| [[Clinical trial]]
| [http://stats.grok.se/en/latest/Clinical_trial chart]
| [http://stats.grok.se/en/201404/Clinical_trial 44417]
|
| align=right | 61329
|
| 15 Nov 12
|
|
|
|-
|-
| [[Febrile neutropenia]]
| [[Febrile neutropenia]]
| [http://stats.grok.se/en/latest/Febrile_neutropenia chart]
| [http://stats.grok.se/en/201404/Febrile_neutropenia 5187]
|
| align=right | 8207
|
| 15 Nov 12
|
|
|
|-
|-
| [[Gleason Grading System]]
| [[Gleason Grading System]]
| [http://stats.grok.se/en/latest/Gleason_Grading_System chart]
| [http://stats.grok.se/en/201404/Gleason_Grading_System 14684]
|
| align=right | 15892
|
| 15 Nov 12
|
|
|
|-
|-
| [[Granulocyte colony-stimulating factor]]
| [[Granulocyte colony-stimulating factor]]
| [http://stats.grok.se/en/latest/Granulocyte_colony-stimulating_factor chart]
| [http://stats.grok.se/en/201404/Granulocyte_colony-stimulating_factor 8091]
|
| align=right | 9389
|
| 15 Nov 12
|
|
|
|-
| ''[[Journal of Clinical Oncology]]''
| [http://stats.grok.se/en/latest/Journal_of_Clinical_Oncology chart]
| align=right | 978
| 15 Nov 12
|
|
|
|-
|-
| [[Mammary ductal carcinoma]]
| [[Mammary ductal carcinoma]]
| [http://stats.grok.se/en/latest/Mammary_ductal_carcinoma chart]
| [http://stats.grok.se/en/201404/Mammary_ductal_carcinoma 9062]
|
| align=right | 16301
|
| 15 Nov 12
|
|
|
|-
|-
| [[Management of cancer]]
| [[Management of cancer]]
| [http://stats.grok.se/en/latest/Management_of_cancer chart]
| [http://stats.grok.se/en/201404/Management_of_cancer 4196]
|
| align=right | 6003
|
| 15 Nov 12
|
|
|
|-
|-
| [[Metastasis]]
| [[Metastasis]]
| [http://stats.grok.se/en/latest/Metastasis chart]
| [http://stats.grok.se/en/201404/Metastasis 56032]
|
| align=right | 80486
|
| 15 Nov 12
|
|
|
|-
| [[Palliative care]]
| [http://stats.grok.se/en/latest/Palliative_care chart]
| align=right | 102952
| 15 Nov 12
|
|
|
|-
|-
| [[Performance status]]
| [[Performance status]]
| [http://stats.grok.se/en/latest/Peformance_status chart]
| [http://stats.grok.se/en/201404/Performance_status 9183]
|
| align=right | 10604
|
| 16 Nov 12
|
|
|
|-
|-
| [[Positron emission tomography]]
| [[Positron emission tomography]]
| [http://stats.grok.se/en/latest/Positron_emission_tomography chart]
| [http://stats.grok.se/en/201404/Positron_emission_tomography 53451]
|
| align=right | 83062
|
| 15 Nov 12
|
|
|
|-
| [[Prostate cancer]]
| [http://stats.grok.se/en/latest/Prostate_cancer chart]
| align=right | 121157
| 15 Nov 12
|
|
|
|-
|-
| [[Prostate cancer staging]]
| [[Prostate cancer staging]]
| [http://stats.grok.se/en/latest/Prostate_cancer_staging chart]
| [http://stats.grok.se/en/201404/Prostate_cancer_staging 4003]
|
| align=right | 6285
|
| 16 Nov 12
|
|
|
|-
|-
| [[Tumor]]
| [[Tumor]]
| [http://stats.grok.se/en/latest/Tumor chart]
| [http://stats.grok.se/en/201404/Tumor 11708]
|
| align=right | 39454
|
| 15 Nov 12
|
|
|
|-
|-
| [[Tumor marker]]
| [[Tumor marker]]
| [http://stats.grok.se/en/latest/Tumor_marker chart]
| [http://stats.grok.se/en/201404/Tumor_marker 11374]
|
| align=right | 13432
|
| 15 Nov 12
|
|
|
|-
|-
|}
|}
{{Wikipedia:Choosing Wisely/template:Month of traffic}}
*page views are for the 30-day period ending on and including 15 November 2012


==Recent changes==
==Recent changes==
Review changes to all of the articles in the above table by visiting [[Special:RecentChangesLinked/Wikipedia:Choosing_Wisely/ASCOwatch|this watchlist]].
Review changes to all of the articles in the above table by visiting [[Special:RecentChangesLinked/Wikipedia:Choosing Wisely/American Society of Clinical Oncology watchlist|this watchlist]].


==References==
==References==
{{Citation |author1 = American Society of Clinical Oncology |author1-link = American Society of Clinical Oncology |date = 24 April 2014 |title = Ten Things Physicians and Patients Should Question |publisher = American Society of Clinical Oncology |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-society-of-clinical-oncology |accessdate = 25 August 2014}}, which cites
{{collapse top|edit this section to edit references}}
#<!-- 1 -->

#*{{cite journal|last1=Azzoli|first1=CG|last2=Temin|first2=S|last3=Aliff|first3=T|last4=Baker S|first4=Jr|last5=Brahmer|first5=J|last6=Johnson|first6=DH|last7=Laskin|first7=JL|last8=Masters|first8=G|last9=Milton|first9=D|last10=Nordquist|first10=L|last11=Pao|first11=W|last12=Pfister|first12=DG|last13=Piantadosi|first13=S|last14=Schiller|first14=JH|last15=Smith|first15=R|last16=Smith|first16=TJ|last17=Strawn|first17=JR|last18=Trent|first18=D|last19=Giaccone|first19=G|last20=American Society of Clinical|first20=Oncology|title=2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.|journal=Journal of Clinical Oncology|date=Oct 1, 2011|volume=29|issue=28|pages=3825–31|doi=10.1200/JCO.2010.34.2774 |pmid=21900105|pmc=3675703 }}
*<ref name="ASCOfive">{{Citation |author1 = American Society of Clinical Oncology |author1-link = American Society of Clinical Oncology |date = |title = Five Things Physicians and Patients Should Question |publisher = [[American Society of Clinical Oncology]] |work = Choosing Wisely: an initiative of the [[ABIM Foundation]] |page = |url = http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_Amer_Soc_Clin_Onc.pdf |accessdate = August 14 2012}}</ref>
*{{cite journal|last1=Ettinger|first1=DS|last2=Akerley|first2=W|last3=Bepler|first3=G|last4=Blum|first4=MG|last5=Chang|first5=A|last6=Cheney|first6=RT|last7=Chirieac|first7=LR|last8=D'Amico|first8=TA|last9=Demmy|first9=TL|last10=Ganti|first10=AK|last11=Govindan|first11=R|last12=Grannis FW|first12=Jr|last13=Jahan|first13=T|last14=Jahanzeb|first14=M|last15=Johnson|first15=DH|last16=Kessinger|first16=A|last17=Komaki|first17=R|last18=Kong|first18=FM|last19=Kris|first19=MG|last20=Krug|first20=LM|last21=Le|first21=QT|last22=Lennes|first22=IT|last23=Martins|first23=R|last24=O'Malley|first24=J|last25=Osarogiagbon|first25=RU|last26=Otterson|first26=GA|last27=Patel|first27=JD|last28=Pisters|first28=KM|last29=Reckamp|first29=K|last30=Riely|first30=GJ|last31=Rohren|first31=E|last32=Simon|first32=GR|last33=Swanson|first33=SJ|last34=Wood|first34=DE|last35=Yang|first35=SC|last36=NCCN Non-Small Cell Lung Cancer Panel|first36=Members|title=Non-small cell lung cancer.|journal=Journal of the National Comprehensive Cancer Network |date=Jul 2010|volume=8|issue=7|pages=740–801|doi=10.6004/jnccn.2010.0056 |pmid=20679538}}
*<ref name="2011lungcancer">{{cite PMID|21900105}}</ref>
#*{{cite journal|last1=Carlson|first1=RW|last2=Allred|first2=DC|last3=Anderson|first3=BO|last4=Burstein|first4=HJ|last5=Carter|first5=WB|last6=Edge|first6=SB|last7=Erban|first7=JK|last8=Farrar|first8=WB|last9=Goldstein|first9=LJ|last10=Gradishar|first10=WJ|last11=Hayes|first11=DF|last12=Hudis|first12=CA|last13=Jahanzeb|first13=M|last14=Kiel|first14=K|last15=Ljung|first15=BM|last16=Marcom|first16=PK|last17=Mayer|first17=IA|last18=McCormick|first18=B|last19=Nabell|first19=LM|last20=Pierce|first20=LJ|last21=Reed|first21=EC|last22=Smith|first22=ML|last23=Somlo|first23=G|last24=Theriault|first24=RL|last25=Topham|first25=NS|last26=Ward|first26=JH|last27=Winer|first27=EP|last28=Wolff|first28=AC|last29=NCCN Breast Cancer Clinical Practice Guidelines|first29=Panel|title=Breast cancer. Clinical practice guidelines in oncology.|journal=Journal of the National Comprehensive Cancer Network |date=Feb 2009|volume=7|issue=2|pages=122–92|doi=10.6004/jnccn.2009.0012 |pmid=19200416}}
*<ref name="EttingerLungCancer">{{cite PMID|20679538}}</ref>
#*{{cite journal|last1=Engstrom|first1=PF|last2=Arnoletti|first2=JP|last3=Benson AB|first3=3rd|last4=Chen|first4=YJ|last5=Choti|first5=MA|last6=Cooper|first6=HS|last7=Covey|first7=A|last8=Dilawari|first8=RA|last9=Early|first9=DS|last10=Enzinger|first10=PC|last11=Fakih|first11=MG|last12=Fleshman J|first12=Jr|last13=Fuchs|first13=C|last14=Grem|first14=JL|last15=Kiel|first15=K|last16=Knol|first16=JA|last17=Leong|first17=LA|last18=Lin|first18=E|last19=Mulcahy|first19=MF|last20=Rao|first20=S|last21=Ryan|first21=DP|last22=Saltz|first22=L|last23=Shibata|first23=D|last24=Skibber|first24=JM|last25=Sofocleous|first25=C|last26=Thomas|first26=J|last27=Venook|first27=AP|last28=Willett|first28=C|last29=National Comprehensive Cancer|first29=Network|title=NCCN Clinical Practice Guidelines in Oncology: colon cancer.|journal=Journal of the National Comprehensive Cancer Network |date=Sep 2009|volume=7|issue=8|pages=778–831|doi=10.6004/jnccn.2009.0056 |pmid=19755046}}
*<ref name="CarlsonBreast">{{cite PMID|19200416}}</ref>
#*{{cite journal|last1=Smith|first1=Thomas J.|last2=Hillner|first2=Bruce E.|title=Bending the Cost Curve in Cancer Care|journal=New England Journal of Medicine|volume=364|issue=21|year=2011|pages=2060–2065|issn=0028-4793|doi=10.1056/NEJMsb1013826|pmid=21612477 |pmc=4042405 }}
*<ref name="EngstromColon">{{cite PMID|19755046}}</ref>
#*{{cite journal|last1=Peppercorn|first1=J. M.|last2=Smith|first2=T. J.|last3=Helft|first3=P. R.|last4=DeBono|first4=D. J.|last5=Berry|first5=S. R.|last6=Wollins|first6=D. S.|last7=Hayes|first7=D. M.|last8=Von Roenn|first8=J. H.|last9=Schnipper|first9=L. E.| display-authors = 8|title=American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer|journal=Journal of Clinical Oncology|volume=29|issue=6|year=2011|pages=755–760|issn=0732-183X|doi=10.1200/JCO.2010.33.1744|pmid=21263086 }}
*<ref name="SmithHillner">{{cite doi|10.1056/NEJMsb1013826}}</ref>
#<!-- 2 -->
*<ref name="PeppercornSmith">{{cite doi|10.1200/JCO.2010.33.1744}}</ref>
#*{{cite journal|last1=Makarov|first1=DV|last2=Desai|first2=RA|last3=Yu|first3=JB|last4=Sharma|first4=R|last5=Abraham|first5=N|last6=Albertsen|first6=PC|last7=Penson|first7=DF|last8=Gross|first8=CP|title=The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population.|journal=The Journal of Urology|date=Jan 2012|volume=187|issue=1|pages=97–102|doi=10.1016/j.juro.2011.09.042 |pmid=22088337}}
*<ref name="MakarovDesai">{{cite PMID|22088337}}</ref>
*<ref>{{cite web |url= http://www.nccn.org/professionals/physician_gls/f_guidelines.asp |title=NCCN Clinical Practice Guidelines in Oncology |author=National Comprehensive Cancer Network - Prostate |authorlink=National Comprehensive Cancer Network |work=nccn.org |year=2012 [last update] |accessdate=15 November 2012}}</ref>
#*{{cite web |url= http://www.nccn.org/professionals/physician_gls/f_guidelines.asp |title=NCCN Clinical Practice Guidelines in Oncology |author=National Comprehensive Cancer Network - Prostate |authorlink=National Comprehensive Cancer Network |work=nccn.org |year=2012 |accessdate=15 November 2012}}
#*{{cite journal|last1=Thompson|first1=I|last2=Thrasher|first2=JB|last3=Aus|first3=G|last4=Burnett|first4=AL|last5=Canby-Hagino|first5=ED|last6=Cookson|first6=MS|last7=D'Amico|first7=AV|last8=Dmochowski|first8=RR|last9=Eton|first9=DT|last10=Forman|first10=JD|last11=Goldenberg|first11=SL|last12=Hernandez|first12=J|last13=Higano|first13=CS|last14=Kraus|first14=SR|last15=Moul|first15=JW|last16=Tangen|first16=CM|last17=AUA Prostate Cancer Clinical Guideline Update|first17=Panel|title=Guideline for the management of clinically localized prostate cancer: 2007 update.|journal=The Journal of Urology|date=Jun 2007|volume=177|issue=6|pages=2106–31|doi=10.1016/j.juro.2007.03.003|pmid=17509297}}
*<ref name="Thompson">{{cite PMID|17509297}}</ref>
#<!-- 3 -->
*<ref name="CarlsonInvasiveBreast">{{cite PMID|17439758}}</ref>
#*{{cite journal|last1=Carlson|first1=RW|last2=Anderson|first2=BO|last3=Burstein|first3=HJ|last4=Carter|first4=WB|last5=Edge|first5=SB|last6=Farrar|first6=WB|last7=Goldstein|first7=LJ|last8=Gradishar|first8=WJ|last9=Hayes|first9=DF|last10=Hudis|first10=CA|last11=Jahanzeb|first11=M|last12=Ljung|first12=BM|last13=Kiel|first13=K|last14=Marks|first14=LB|last15=McCormick|first15=B|last16=Nabell|first16=LM|last17=Pierce|first17=LJ|last18=Reed|first18=EC|last19=Silver|first19=SM|last20=Smith|first20=ML|last21=Somlo|first21=G|last22=Theriault|first22=RL|last23=Ward|first23=JH|last24=Winer|first24=EP|last25=Wolff|first25=AC|title=Invasive breast cancer.|journal=Journal of the National Comprehensive Cancer Network |date=Mar 2007|volume=5|issue=3|pages=246–312|pmid=17439758}}
*<ref name="LockerHamilton">{{cite doi|10.1200/JCO.2006.08.2644}}</ref>
#<!-- 4 -->
*<ref name="DeschBenson">{{cite PMID|16260687}}</ref>
#*{{cite journal|last1=Locker|first1=G. Y.|last2=Hamilton|first2=S.|last3=Harris|first3=J.|last4=Jessup|first4=J. M.|last5=Kemeny|first5=N.|last6=Macdonald|first6=J. S.|last7=Somerfield|first7=M. R.|last8=Hayes|first8=D. F.|last9=Bast|first9=R. C.| display-authors = 8|title=ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer|journal=Journal of Clinical Oncology|volume=24|issue=33|year=2006|pages=5313–5327|issn=0732-183X|doi=10.1200/JCO.2006.08.2644}}
*<ref name="Khatcheressian">{{cite doi|10.1200/JCO.2006.08.8575}}</ref>
#*{{cite journal|last1=Desch|first1=CE|last2=Benson AB|first2=3rd|last3=Somerfield|first3=MR|last4=Flynn|first4=PJ|last5=Krause|first5=C|last6=Loprinzi|first6=CL|last7=Minsky|first7=BD|last8=Pfister|first8=DG|last9=Virgo|first9=KS|last10=Petrelli|first10=NJ|last11=American Society of Clinical|first11=Oncology|title=Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.|journal=Journal of Clinical Oncology|date=Nov 20, 2005|volume=23|issue=33|pages=8512–9|doi=10.1200/JCO.2005.04.0063 |pmid=16260687}}
*<ref name="HarrisFritsche">{{cite doi|10.1200/JCO.2007.14.2364}}</ref>
#*{{cite journal|last1=Carlson|first1=RW|last2=Allred|first2=DC|last3=Anderson|first3=BO|last4=Burstein|first4=HJ|last5=Carter|first5=WB|last6=Edge|first6=SB|last7=Erban|first7=JK|last8=Farrar|first8=WB|last9=Goldstein|first9=LJ|last10=Gradishar|first10=WJ|last11=Hayes|first11=DF|last12=Hudis|first12=CA|last13=Jahanzeb|first13=M|last14=Kiel|first14=K|last15=Ljung|first15=BM|last16=Marcom|first16=PK|last17=Mayer|first17=IA|last18=McCormick|first18=B|last19=Nabell|first19=LM|last20=Pierce|first20=LJ|last21=Reed|first21=EC|last22=Smith|first22=ML|last23=Somlo|first23=G|last24=Theriault|first24=RL|last25=Topham|first25=NS|last26=Ward|first26=JH|last27=Winer|first27=EP|last28=Wolff|first28=AC|last29=NCCN Breast Cancer Clinical Practice Guidelines|first29=Panel|title=Breast cancer. Clinical practice guidelines in oncology.|journal=Journal of the National Comprehensive Cancer Network |date=Feb 2009|volume=7|issue=2|pages=122–92|doi=10.6004/jnccn.2009.0012 |pmid=19200416}}
*<ref name="SmithKhatcheressianWhiteBlood">{{cite doi|10.1200/JCO.2006.06.4451 }}</ref>
#*{{cite journal|last1=Khatcheressian|first1=J. L.|last2=Wolff|first2=A. C.|last3=Smith|first3=T. J.|last4=Grunfeld|first4=E.|last5=Muss|first5=H. B.|last6=Vogel|first6=V. G.|last7=Halberg|first7=F.|last8=Somerfield|first8=M. R.|last9=Davidson|first9=N. E.| display-authors = 8|title=American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting|journal=Journal of Clinical Oncology|volume=24|issue=31|year=2006|pages=5091–5097|issn=0732-183X|doi=10.1200/JCO.2006.08.8575}}

#*{{cite journal|last1=Harris|first1=L.|last2=Fritsche|first2=H.|last3=Mennel|first3=R.|last4=Norton|first4=L.|last5=Ravdin|first5=P.|last6=Taube|first6=S.|last7=Somerfield|first7=M. R.|last8=Hayes|first8=D. F.|last9=Bast|first9=R. C.| display-authors = 8|title=American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer|journal=Journal of Clinical Oncology|volume=25|issue=33|year=2007|pages=5287–5312|issn=0732-183X|doi=10.1200/JCO.2007.14.2364|pmid=17954709 }}
{{collapse bottom}}
#<!-- 5 -->
#*{{cite journal|last1=Smith|first1=T. J.|title=2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline|journal=Journal of Clinical Oncology|volume=24|issue=19|year=2006|pages=3187–3205|issn=0732-183X|doi=10.1200/JCO.2006.06.4451|pmid=16682719 }}
#<!-- 6 -->
#*{{cite journal|last1=Basch|first1=E.|last2=Prestrud|first2=A. A.|last3=Hesketh|first3=P. J.|last4=Kris|first4=M. G.|last5=Feyer|first5=P. C.|last6=Somerfield|first6=M. R.|last7=Chesney|first7=M.|last8=Clark-Snow|first8=R. A.|last9=Flaherty|first9=A. M.|last10=Freundlich|first10=B.|last11=Morrow|first11=G.|last12=Rao|first12=K. V.|last13=Schwartz|first13=R. N.|last14=Lyman|first14=G. H.|title=Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update|journal=Journal of Clinical Oncology|volume=29|issue=31|year=2011|pages=4189–4198|issn=0732-183X|doi=10.1200/JCO.2010.34.4614|pmid=21947834 |pmc=4876353 }}
#*{{cite journal|last1=Saito|first1=Mitsue|last2=Aogi|first2=Kenjiro|last3=Sekine|first3=Ikuo|last4=Yoshizawa|first4=Hirohisa|last5=Yanagita|first5=Yasuhiro|last6=Sakai|first6=Hiroshi|last7=Inoue|first7=Kenichi|last8=Kitagawa|first8=Chiyoe|last9=Ogura|first9=Takashi|last10=Mitsuhashi|first10=Shoichi|title=Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial|journal=The Lancet Oncology|volume=10|issue=2|year=2009|pages=115–124|issn=1470-2045|doi=10.1016/S1470-2045(08)70313-9|pmid=19135415 }}
#*{{cite journal|last1=Aapro|first1=M.|last2=Fabi|first2=A.|last3=Nole|first3=F.|last4=Medici|first4=M.|last5=Steger|first5=G.|last6=Bachmann|first6=C.|last7=Roncoroni|first7=S.|last8=Roila|first8=F.|title=Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy|journal=Annals of Oncology|volume=21|issue=5|year=2010|pages=1083–1088|issn=0923-7534|doi=10.1093/annonc/mdp584|pmid=20080830 }}
#*{{cite journal|last1=Yu|first1=Zhaocai|last2=Liu|first2=Wenchao|last3=Wang|first3=Ling|last4=Liang|first4=Houjie|last5=Huang|first5=Ying|last6=Si|first6=Xiaoming|last7=Zhang|first7=Helong|last8=Liu|first8=Duhu|last9=Zhang|first9=Hongmei| display-authors = 8|title=The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial|journal=Supportive Care in Cancer|volume=17|issue=1|year=2008|pages=99–102|issn=0941-4355|doi=10.1007/s00520-008-0503-4|pmid=18825421 |s2cid=20555095 }}
#<!-- 7 -->
#*{{cite journal|last1=Cardoso|first1=F.|last2=Costa|first2=A.|last3=Norton|first3=L.|last4=Cameron|first4=D.|last5=Cufer|first5=T.|last6=Fallowfield|first6=L.|last7=Francis|first7=P.|last8=Gligorov|first8=J.|last9=Kyriakides|first9=S.|last10=Lin|first10=N.|last11=Pagani|first11=O.|last12=Senkus|first12=E.|last13=Thomssen|first13=C.|last14=Aapro|first14=M.|last15=Bergh|first15=J.|last16=Di Leo|first16=A.|last17=El Saghir|first17=N.|last18=Ganz|first18=P.A.|last19=Gelmon|first19=K.|last20=Goldhirsch|first20=A.|last21=Harbeck|first21=N.|last22=Houssami|first22=N.|last23=Hudis|first23=C.|last24=Kaufman|first24=B.|last25=Leadbeater|first25=M.|last26=Mayer|first26=M.|last27=Rodger|first27=A.|last28=Rugo|first28=H.|last29=Sacchini|first29=V.|last30=Sledge|first30=G.|last31=van’t Veer|first31=L.|last32=Viale|first32=G.|last33=Krop|first33=I.|last34=Winer|first34=E.|title=1st International consensus guidelines for advanced breast cancer (ABC 1)|journal=The Breast|volume=21|issue=3|year=2012|pages=242–252|issn=0960-9776|doi=10.1016/j.breast.2012.03.003}}
#*{{cite journal|last1=Carrick|first1=Sue|last2=Parker|first2=Sharon|last3=Thornton|first3=Charlene E|last4=Ghersi|first4=Davina|last5=Simes|first5=John|last6=Wilcken|first6=Nicholas|last7=Carrick|first7=Sue|title=Single agent versus combination chemotherapy for metastatic breast cancer|journal=Cochrane Database of Systematic Reviews |year=2009|volume=2021 |issue=5 |doi=10.1002/14651858.CD003372.pub3|pmid=19370586 }}
#*{{cite journal|last1=Zelenetz|first1=AD|last2=Abramson|first2=JS|last3=Advani|first3=RH|last4=Andreadis|first4=CB|last5=Byrd|first5=JC|last6=Czuczman|first6=MS|last7=Fayad|first7=L|last8=Forero|first8=A|last9=Glenn|first9=MJ|last10=Gockerman|first10=JP|last11=Gordon|first11=LI|last12=Harris|first12=NL|last13=Hoppe|first13=RT|last14=Horwitz|first14=SM|last15=Kaminski|first15=MS|last16=Kim|first16=YH|last17=Lacasce|first17=AS|last18=Mughal|first18=TI|last19=Nademanee|first19=A|last20=Porcu|first20=P|last21=Press|first21=O|last22=Prosnitz|first22=L|last23=Reddy|first23=N|last24=Smith|first24=MR|last25=Sokol|first25=L|last26=Swinnen|first26=L|last27=Vose|first27=JM|last28=Wierda|first28=WG|last29=Yahalom|first29=J|last30=Yunus|first30=F|title=NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.|journal=Journal of the National Comprehensive Cancer Network |date=Mar 2010|volume=8|issue=3|pages=288–334|doi=10.6004/jnccn.2010.0021 |pmid=20202462}}
#*{{cite journal|last1=Slamon|first1=Dennis J.|last2=Leyland-Jones|first2=Brian|last3=Shak|first3=Steven|last4=Fuchs|first4=Hank|last5=Paton|first5=Virginia|last6=Bajamonde|first6=Alex|last7=Fleming|first7=Thomas|last8=Eiermann|first8=Wolfgang|last9=Wolter|first9=Janet|last10=Pegram|first10=Mark|last11=Baselga|first11=Jose|last12=Norton|first12=Larry|title=Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2|journal=New England Journal of Medicine|volume=344|issue=11|year=2001|pages=783–792|issn=0028-4793|doi=10.1056/NEJM200103153441101|pmid=11248153 }}
#*{{cite journal|last1=Howell|first1=A.|title=Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment|journal=Journal of Clinical Oncology|volume=20|issue=16|year=2002|pages=3396–3403|issn=0732-183X|doi=10.1200/JCO.2002.10.057}}
#*{{cite journal|last1=Lutz|first1=Stephen|last2=Berk|first2=Lawrence|last3=Chang|first3=Eric|last4=Chow|first4=Edward|last5=Hahn|first5=Carol|last6=Hoskin|first6=Peter|last7=Howell|first7=David|last8=Konski|first8=Andre|last9=Kachnic|first9=Lisa|last10=Lo|first10=Simon|last11=Sahgal|first11=Arjun|last12=Silverman|first12=Larry|last13=von Gunten|first13=Charles|last14=Mendel|first14=Ehud|last15=Vassil|first15=Andrew|last16=Bruner|first16=Deborah Watkins|last17=Hartsell|first17=William|title=Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline|journal=International Journal of Radiation Oncology*Biology*Physics|volume=79|issue=4|year=2011|pages=965–976|issn=0360-3016|doi=10.1016/j.ijrobp.2010.11.026}}
#<!-- 8 -->
#*{{cite web |url= http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=263 |title=Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4) |author=Centers for Medicare and Medicaid Services |authorlink=Centers for Medicare and Medicaid Services|work=cms.gov |date=June 11, 2013 |accessdate=3 September 2014}}
#*{{cite web |url= https://www.cancercare.on.ca/ocs/clinicalprogs/imaging/pet |title=PET Imaging in Ontario - CCO |author=Cancer Care Ontario |authorlink=Cancer Care Ontario |work=cancercare.on.ca |date=May 28, 2012 |accessdate=3 September 2014}}
#*{{cite journal|last1=Labianca|first1=R.|last2=Nordlinger|first2=B.|last3=Beretta|first3=G. D.|last4=Brouquet|first4=A.|last5=Cervantes|first5=A.|title=Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up|journal=Annals of Oncology|volume=21|issue=Supplement 5|year=2010|pages=v70–v77|issn=0923-7534|doi=10.1093/annonc/mdq168|pmid=20555107 }}
#<!-- 9 -->
#*{{cite journal|last1=Raghavan|first1=Derek|title=PSA: Please Stop Agonizing (Over Prostate-Specific Antigen Interpretation)|journal=Mayo Clinic Proceedings|volume=88|issue=1|year=2013|pages=1–3|issn=0025-6196|doi=10.1016/j.mayocp.2012.11.004}}
#*{{cite journal|last1=Schröder|first1=Fritz H.|last2=Hugosson|first2=Jonas|last3=Roobol|first3=Monique J.|last4=Tammela|first4=Teuvo L.J.|last5=Ciatto|first5=Stefano|last6=Nelen|first6=Vera|last7=Kwiatkowski|first7=Maciej|last8=Lujan|first8=Marcos|last9=Lilja|first9=Hans|last10=Zappa|first10=Marco|last11=Denis|first11=Louis J.|last12=Recker|first12=Franz|last13=Páez|first13=Alvaro|last14=Määttänen|first14=Liisa|last15=Bangma|first15=Chris H.|last16=Aus|first16=Gunnar|last17=Carlsson|first17=Sigrid|last18=Villers|first18=Arnauld|last19=Rebillard|first19=Xavier|last20=van der Kwast|first20=Theodorus|last21=Kujala|first21=Paula M.|last22=Blijenberg|first22=Bert G.|last23=Stenman|first23=Ulf-Hakan|last24=Huber|first24=Andreas|last25=Taari|first25=Kimmo|last26=Hakama|first26=Matti|last27=Moss|first27=Sue M.|last28=de Koning|first28=Harry J.|last29=Auvinen|first29=Anssi|title=Prostate-Cancer Mortality at 11 Years of Follow-up|journal=New England Journal of Medicine|volume=366|issue=11|year=2012|pages=981–990|issn=0028-4793|doi=10.1056/NEJMoa1113135|pmid=22417251 |pmc=6027585 }}
#*{{cite journal|last1=Hugosson|first1=Jonas|last2=Carlsson|first2=Sigrid|last3=Aus|first3=Gunnar|last4=Bergdahl|first4=Svante|last5=Khatami|first5=Ali|last6=Lodding|first6=Pär|last7=Pihl|first7=Carl-Gustaf|last8=Stranne|first8=Johan|last9=Holmberg|first9=Erik|last10=Lilja|first10=Hans|title=Mortality results from the Göteborg randomised population-based prostate-cancer screening trial|journal=The Lancet Oncology|volume=11|issue=8|year=2010|pages=725–732|issn=1470-2045|doi=10.1016/S1470-2045(10)70146-7|pmid=20598634 |pmc=4089887 }}
#*{{cite journal|last1=Andriole|first1=Gerald L.|last2=Crawford|first2=E. David|last3=Grubb|first3=Robert L.|last4=Buys|first4=Saundra S.|last5=Chia|first5=David|last6=Church|first6=Timothy R.|last7=Fouad|first7=Mona N.|last8=Gelmann|first8=Edward P.|last9=Kvale|first9=Paul A.|last10=Reding|first10=Douglas J.|last11=Weissfeld|first11=Joel L.|last12=Yokochi|first12=Lance A.|last13=O'Brien|first13=Barbara|last14=Clapp|first14=Jonathan D.|last15=Rathmell|first15=Joshua M.|last16=Riley|first16=Thomas L.|last17=Hayes|first17=Richard B.|last18=Kramer|first18=Barnett S.|last19=Izmirlian|first19=Grant|last20=Miller|first20=Anthony B.|last21=Pinsky|first21=Paul F.|last22=Prorok|first22=Philip C.|last23=Gohagan|first23=John K.|last24=Berg|first24=Christine D.|title=Mortality Results from a Randomized Prostate-Cancer Screening Trial|journal=New England Journal of Medicine|volume=360|issue=13|year=2009|pages=1310–1319|issn=0028-4793|doi=10.1056/NEJMoa0810696|pmid=19297565 |pmc=2944770 }}
#*{{cite journal|last1=Moyer|first1=Virginia A.|title=Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|volume=157|issue=2|year=2012|pages=120–134|issn=0003-4819|doi=10.7326/0003-4819-157-2-201207170-00459|pmid=22801674 |s2cid=951709 }}
#*{{cite journal|last1=Qaseem|first1=Amir|title=Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians|journal=Annals of Internal Medicine|volume=158|issue=10|year=2013|pages=761|issn=0003-4819|doi=10.7326/0003-4819-158-10-201305210-00633|s2cid=20366476 }}
#*{{cite journal|last1=Qaseem|first1=Amir|title=Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians|journal=Annals of Internal Medicine|volume=158|issue=10|year=2013|pages=761|issn=0003-4819|doi=10.7326/0003-4819-158-10-201305210-00633|s2cid=20366476 }}
#*{{cite journal|last1=Basch|first1=E.|last2=Oliver|first2=T. K.|last3=Vickers|first3=A.|last4=Thompson|first4=I.|last5=Kantoff|first5=P.|last6=Parnes|first6=H.|last7=Loblaw|first7=D. A.|last8=Roth|first8=B.|last9=Williams|first9=J.|last10=Nam|first10=R. K.|title=Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion|journal=Journal of Clinical Oncology|volume=30|issue=24|year=2012|pages=3020–3025|issn=0732-183X|doi=10.1200/JCO.2012.43.3441|pmid=22802323 |pmc=3776923 }}
#<!-- 10 -->
#*{{cite journal|last1=Shaw|first1=Alice T.|last2=Kim|first2=Dong-Wan|last3=Nakagawa|first3=Kazuhiko|last4=Seto|first4=Takashi|last5=Crinó|first5=Lucio|last6=Ahn|first6=Myung-Ju|last7=De Pas|first7=Tommaso|last8=Besse|first8=Benjamin|last9=Solomon|first9=Benjamin J.|last10=Blackhall|first10=Fiona|last11=Wu|first11=Yi-Long|last12=Thomas|first12=Michael|last13=O'Byrne|first13=Kenneth J.|last14=Moro-Sibilot|first14=Denis|last15=Camidge|first15=D. Ross|last16=Mok|first16=Tony|last17=Hirsh|first17=Vera|last18=Riely|first18=Gregory J.|last19=Iyer|first19=Shrividya|last20=Tassell|first20=Vanessa|last21=Polli|first21=Anna|last22=Wilner|first22=Keith D.|last23=Jänne|first23=Pasi A.|title=Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer|journal=New England Journal of Medicine|volume=368|issue=25|year=2013|pages=2385–2394|issn=0028-4793|doi=10.1056/NEJMoa1214886|pmid=23724913|s2cid=19466284 |url=https://www.research.manchester.ac.uk/portal/en/publications/crizotinib-versus-chemotherapy-in-advanced-alkpositive-lung-cancer(8fa2dec0-56bd-4751-abd7-6077f088d1f1).html }}
#*{{cite journal|last1=Sequist|first1=L. V.|last2=Yang|first2=J. C.-H.|last3=Yamamoto|first3=N.|last4=O'Byrne|first4=K.|last5=Hirsh|first5=V.|last6=Mok|first6=T.|last7=Geater|first7=S. L.|last8=Orlov|first8=S.|last9=Tsai|first9=C.-M.|last10=Boyer|first10=M.|last11=Su|first11=W.-C.|last12=Bennouna|first12=J.|last13=Kato|first13=T.|last14=Gorbunova|first14=V.|last15=Lee|first15=K. H.|last16=Shah|first16=R.|last17=Massey|first17=D.|last18=Zazulina|first18=V.|last19=Shahidi|first19=M.|last20=Schuler|first20=M.|title=Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations|journal=Journal of Clinical Oncology|volume=31|issue=27|year=2013|pages=3327–3334|issn=0732-183X|doi=10.1200/JCO.2012.44.2806|pmid=23816960}}
#*{{cite journal|last1=Chapman|first1=Paul B.|last2=Hauschild|first2=Axel|last3=Robert|first3=Caroline|last4=Haanen|first4=John B.|last5=Ascierto|first5=Paolo|last6=Larkin|first6=James|last7=Dummer|first7=Reinhard|last8=Garbe|first8=Claus|last9=Testori|first9=Alessandro|last10=Maio|first10=Michele|last11=Hogg|first11=David|last12=Lorigan|first12=Paul|last13=Lebbe|first13=Celeste|last14=Jouary|first14=Thomas|last15=Schadendorf|first15=Dirk|last16=Ribas|first16=Antoni|last17=O'Day|first17=Steven J.|last18=Sosman|first18=Jeffrey A.|last19=Kirkwood|first19=John M.|last20=Eggermont|first20=Alexander M.M.|last21=Dreno|first21=Brigitte|last22=Nolop|first22=Keith|last23=Li|first23=Jiang|last24=Nelson|first24=Betty|last25=Hou|first25=Jeannie|last26=Lee|first26=Richard J.|last27=Flaherty|first27=Keith T.|last28=McArthur|first28=Grant A.|title=Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation|journal=New England Journal of Medicine|volume=364|issue=26|year=2011|pages=2507–2516|issn=0028-4793|doi=10.1056/NEJMoa1103782|pmid=21639808|url=https://www.research.manchester.ac.uk/portal/en/publications/improved-survival-with-vemurafenib-in-melanoma-with-braf-v600e-mutation(6f134d68-811a-43ec-a343-ee049b169b97).html }}
#*{{cite journal|last1=Lynch|first1=Thomas J.|last2=Bell|first2=Daphne W.|last3=Sordella|first3=Raffaella|last4=Gurubhagavatula|first4=Sarada|last5=Okimoto|first5=Ross A.|last6=Brannigan|first6=Brian W.|last7=Harris|first7=Patricia L.|last8=Haserlat|first8=Sara M.|last9=Supko|first9=Jeffrey G.|last10=Haluska|first10=Frank G.|last11=Louis|first11=David N.|last12=Christiani|first12=David C.|last13=Settleman|first13=Jeff|last14=Haber|first14=Daniel A.|title=Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib|journal=New England Journal of Medicine|volume=350|issue=21|year=2004|pages=2129–2139|issn=0028-4793|doi=10.1056/NEJMoa040938|pmid=15118073|url=http://repository.cshl.edu/22429/1/EGFR%20Mutations.pdf }}
#*{{cite journal|last1=Keedy|first1=V. L.|last2=Temin|first2=S.|last3=Somerfield|first3=M. R.|last4=Beasley|first4=M. B.|last5=Johnson|first5=D. H.|last6=McShane|first6=L. M.|last7=Milton|first7=D. T.|last8=Strawn|first8=J. R.|last9=Wakelee|first9=H. A.|last10=Giaccone|first10=G.|title=American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy|journal=Journal of Clinical Oncology|volume=29|issue=15|year=2011|pages=2121–2127|issn=0732-183X|doi=10.1200/JCO.2010.31.8923|pmid=21482992}}
#*{{cite journal|last1=Allegra|first1=C. J.|last2=Jessup|first2=J. M.|last3=Somerfield|first3=M. R.|last4=Hamilton|first4=S. R.|last5=Hammond|first5=E. H.|last6=Hayes|first6=D. F.|last7=McAllister|first7=P. K.|last8=Morton|first8=R. F.|last9=Schilsky|first9=R. L.| display-authors = 8|title=American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy|journal=Journal of Clinical Oncology|volume=27|issue=12|year=2009|pages=2091–2096|issn=0732-183X|doi=10.1200/JCO.2009.21.9170|pmid=19188670}}


{{reflist}}
{{reflist}}

Latest revision as of 19:47, 19 June 2022

This project shares information from the American Society of Clinical Oncology on Wikipedia.

Articles of interest

[edit]
Articles relating to American Society of Clinical Oncology content
article traffic in April 2014* sources cited change summary
American Society of Clinical Oncology 1137
Breast cancer 66939 history
Breast cancer treatment 605 3 recommend against a physician's use of PET scans, CT scans, or bone scans when staging early breast cancer with low risk for metastasis
Cancer 138119 1 In some cases, medical specialty professional organizations recommend that patients and physicians respond to cancer only with palliative care and not with cancer-directed therapy
Cancer staging 25644 2, 3 recommend against the use of PET scans, CT scans, or bone scans because research shows that the risk of getting such procedures outweighs the possible benefits
Palliative care 61724 1 In some cases, medical specialty professional organizations recommend that patients and physicians respond to cancer only with palliative care and not with cancer-directed therapy
Prostate cancer 64413
Chemotherapy 71985
Clinical trial 44417
Febrile neutropenia 5187
Gleason Grading System 14684
Granulocyte colony-stimulating factor 8091
Mammary ductal carcinoma 9062
Management of cancer 4196
Metastasis 56032
Performance status 9183
Positron emission tomography 53451
Prostate cancer staging 4003
Tumor 11708
Tumor marker 11374
  • *An arbitrary month has been chosen to present a count of pageviews. This month is neither the busiest nor slowest month, and this number seems typical for most articles in most months. Through the link anyone may check traffic in other months.

Recent changes

[edit]

Review changes to all of the articles in the above table by visiting this watchlist.

References

[edit]

American Society of Clinical Oncology (24 April 2014), "Ten Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Society of Clinical Oncology, retrieved 25 August 2014, which cites

  • Ettinger, DS; Akerley, W; Bepler, G; Blum, MG; Chang, A; Cheney, RT; Chirieac, LR; D'Amico, TA; Demmy, TL; Ganti, AK; Govindan, R; Grannis FW, Jr; Jahan, T; Jahanzeb, M; Johnson, DH; Kessinger, A; Komaki, R; Kong, FM; Kris, MG; Krug, LM; Le, QT; Lennes, IT; Martins, R; O'Malley, J; Osarogiagbon, RU; Otterson, GA; Patel, JD; Pisters, KM; Reckamp, K; Riely, GJ; Rohren, E; Simon, GR; Swanson, SJ; Wood, DE; Yang, SC; NCCN Non-Small Cell Lung Cancer Panel, Members (Jul 2010). "Non-small cell lung cancer". Journal of the National Comprehensive Cancer Network. 8 (7): 740–801. doi:10.6004/jnccn.2010.0056. PMID 20679538.
    • Carlson, RW; Allred, DC; Anderson, BO; Burstein, HJ; Carter, WB; Edge, SB; Erban, JK; Farrar, WB; Goldstein, LJ; Gradishar, WJ; Hayes, DF; Hudis, CA; Jahanzeb, M; Kiel, K; Ljung, BM; Marcom, PK; Mayer, IA; McCormick, B; Nabell, LM; Pierce, LJ; Reed, EC; Smith, ML; Somlo, G; Theriault, RL; Topham, NS; Ward, JH; Winer, EP; Wolff, AC; NCCN Breast Cancer Clinical Practice Guidelines, Panel (Feb 2009). "Breast cancer. Clinical practice guidelines in oncology". Journal of the National Comprehensive Cancer Network. 7 (2): 122–92. doi:10.6004/jnccn.2009.0012. PMID 19200416.
    • Engstrom, PF; Arnoletti, JP; Benson AB, 3rd; Chen, YJ; Choti, MA; Cooper, HS; Covey, A; Dilawari, RA; Early, DS; Enzinger, PC; Fakih, MG; Fleshman J, Jr; Fuchs, C; Grem, JL; Kiel, K; Knol, JA; Leong, LA; Lin, E; Mulcahy, MF; Rao, S; Ryan, DP; Saltz, L; Shibata, D; Skibber, JM; Sofocleous, C; Thomas, J; Venook, AP; Willett, C; National Comprehensive Cancer, Network (Sep 2009). "NCCN Clinical Practice Guidelines in Oncology: colon cancer". Journal of the National Comprehensive Cancer Network. 7 (8): 778–831. doi:10.6004/jnccn.2009.0056. PMID 19755046.{{cite journal}}: CS1 maint: numeric names: authors list (link)
    • Smith, Thomas J.; Hillner, Bruce E. (2011). "Bending the Cost Curve in Cancer Care". New England Journal of Medicine. 364 (21): 2060–2065. doi:10.1056/NEJMsb1013826. ISSN 0028-4793. PMC 4042405. PMID 21612477.
    • Peppercorn, J. M.; Smith, T. J.; Helft, P. R.; DeBono, D. J.; Berry, S. R.; Wollins, D. S.; Hayes, D. M.; Von Roenn, J. H.; et al. (2011). "American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer". Journal of Clinical Oncology. 29 (6): 755–760. doi:10.1200/JCO.2010.33.1744. ISSN 0732-183X. PMID 21263086.
    • Makarov, DV; Desai, RA; Yu, JB; Sharma, R; Abraham, N; Albertsen, PC; Penson, DF; Gross, CP (Jan 2012). "The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population". The Journal of Urology. 187 (1): 97–102. doi:10.1016/j.juro.2011.09.042. PMID 22088337.
    • National Comprehensive Cancer Network - Prostate (2012). "NCCN Clinical Practice Guidelines in Oncology". nccn.org. Retrieved 15 November 2012.
    • Thompson, I; Thrasher, JB; Aus, G; Burnett, AL; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, CM; AUA Prostate Cancer Clinical Guideline Update, Panel (Jun 2007). "Guideline for the management of clinically localized prostate cancer: 2007 update". The Journal of Urology. 177 (6): 2106–31. doi:10.1016/j.juro.2007.03.003. PMID 17509297.
    • Carlson, RW; Anderson, BO; Burstein, HJ; Carter, WB; Edge, SB; Farrar, WB; Goldstein, LJ; Gradishar, WJ; Hayes, DF; Hudis, CA; Jahanzeb, M; Ljung, BM; Kiel, K; Marks, LB; McCormick, B; Nabell, LM; Pierce, LJ; Reed, EC; Silver, SM; Smith, ML; Somlo, G; Theriault, RL; Ward, JH; Winer, EP; Wolff, AC (Mar 2007). "Invasive breast cancer". Journal of the National Comprehensive Cancer Network. 5 (3): 246–312. PMID 17439758.
    • Locker, G. Y.; Hamilton, S.; Harris, J.; Jessup, J. M.; Kemeny, N.; Macdonald, J. S.; Somerfield, M. R.; Hayes, D. F.; et al. (2006). "ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer". Journal of Clinical Oncology. 24 (33): 5313–5327. doi:10.1200/JCO.2006.08.2644. ISSN 0732-183X.
    • Desch, CE; Benson AB, 3rd; Somerfield, MR; Flynn, PJ; Krause, C; Loprinzi, CL; Minsky, BD; Pfister, DG; Virgo, KS; Petrelli, NJ; American Society of Clinical, Oncology (Nov 20, 2005). "Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline". Journal of Clinical Oncology. 23 (33): 8512–9. doi:10.1200/JCO.2005.04.0063. PMID 16260687.{{cite journal}}: CS1 maint: numeric names: authors list (link)
    • Carlson, RW; Allred, DC; Anderson, BO; Burstein, HJ; Carter, WB; Edge, SB; Erban, JK; Farrar, WB; Goldstein, LJ; Gradishar, WJ; Hayes, DF; Hudis, CA; Jahanzeb, M; Kiel, K; Ljung, BM; Marcom, PK; Mayer, IA; McCormick, B; Nabell, LM; Pierce, LJ; Reed, EC; Smith, ML; Somlo, G; Theriault, RL; Topham, NS; Ward, JH; Winer, EP; Wolff, AC; NCCN Breast Cancer Clinical Practice Guidelines, Panel (Feb 2009). "Breast cancer. Clinical practice guidelines in oncology". Journal of the National Comprehensive Cancer Network. 7 (2): 122–92. doi:10.6004/jnccn.2009.0012. PMID 19200416.
    • Khatcheressian, J. L.; Wolff, A. C.; Smith, T. J.; Grunfeld, E.; Muss, H. B.; Vogel, V. G.; Halberg, F.; Somerfield, M. R.; et al. (2006). "American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting". Journal of Clinical Oncology. 24 (31): 5091–5097. doi:10.1200/JCO.2006.08.8575. ISSN 0732-183X.
    • Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; et al. (2007). "American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer". Journal of Clinical Oncology. 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. ISSN 0732-183X. PMID 17954709.
    • Smith, T. J. (2006). "2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline". Journal of Clinical Oncology. 24 (19): 3187–3205. doi:10.1200/JCO.2006.06.4451. ISSN 0732-183X. PMID 16682719.
    • Basch, E.; Prestrud, A. A.; Hesketh, P. J.; Kris, M. G.; Feyer, P. C.; Somerfield, M. R.; Chesney, M.; Clark-Snow, R. A.; Flaherty, A. M.; Freundlich, B.; Morrow, G.; Rao, K. V.; Schwartz, R. N.; Lyman, G. H. (2011). "Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update". Journal of Clinical Oncology. 29 (31): 4189–4198. doi:10.1200/JCO.2010.34.4614. ISSN 0732-183X. PMC 4876353. PMID 21947834.
    • Saito, Mitsue; Aogi, Kenjiro; Sekine, Ikuo; Yoshizawa, Hirohisa; Yanagita, Yasuhiro; Sakai, Hiroshi; Inoue, Kenichi; Kitagawa, Chiyoe; Ogura, Takashi; Mitsuhashi, Shoichi (2009). "Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial". The Lancet Oncology. 10 (2): 115–124. doi:10.1016/S1470-2045(08)70313-9. ISSN 1470-2045. PMID 19135415.
    • Aapro, M.; Fabi, A.; Nole, F.; Medici, M.; Steger, G.; Bachmann, C.; Roncoroni, S.; Roila, F. (2010). "Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy". Annals of Oncology. 21 (5): 1083–1088. doi:10.1093/annonc/mdp584. ISSN 0923-7534. PMID 20080830.
    • Yu, Zhaocai; Liu, Wenchao; Wang, Ling; Liang, Houjie; Huang, Ying; Si, Xiaoming; Zhang, Helong; Liu, Duhu; et al. (2008). "The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial". Supportive Care in Cancer. 17 (1): 99–102. doi:10.1007/s00520-008-0503-4. ISSN 0941-4355. PMID 18825421. S2CID 20555095.
    • Cardoso, F.; Costa, A.; Norton, L.; Cameron, D.; Cufer, T.; Fallowfield, L.; Francis, P.; Gligorov, J.; Kyriakides, S.; Lin, N.; Pagani, O.; Senkus, E.; Thomssen, C.; Aapro, M.; Bergh, J.; Di Leo, A.; El Saghir, N.; Ganz, P.A.; Gelmon, K.; Goldhirsch, A.; Harbeck, N.; Houssami, N.; Hudis, C.; Kaufman, B.; Leadbeater, M.; Mayer, M.; Rodger, A.; Rugo, H.; Sacchini, V.; Sledge, G.; van’t Veer, L.; Viale, G.; Krop, I.; Winer, E. (2012). "1st International consensus guidelines for advanced breast cancer (ABC 1)". The Breast. 21 (3): 242–252. doi:10.1016/j.breast.2012.03.003. ISSN 0960-9776.
    • Carrick, Sue; Parker, Sharon; Thornton, Charlene E; Ghersi, Davina; Simes, John; Wilcken, Nicholas; Carrick, Sue (2009). "Single agent versus combination chemotherapy for metastatic breast cancer". Cochrane Database of Systematic Reviews. 2021 (5). doi:10.1002/14651858.CD003372.pub3. PMID 19370586.
    • Zelenetz, AD; Abramson, JS; Advani, RH; Andreadis, CB; Byrd, JC; Czuczman, MS; Fayad, L; Forero, A; Glenn, MJ; Gockerman, JP; Gordon, LI; Harris, NL; Hoppe, RT; Horwitz, SM; Kaminski, MS; Kim, YH; Lacasce, AS; Mughal, TI; Nademanee, A; Porcu, P; Press, O; Prosnitz, L; Reddy, N; Smith, MR; Sokol, L; Swinnen, L; Vose, JM; Wierda, WG; Yahalom, J; Yunus, F (Mar 2010). "NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas". Journal of the National Comprehensive Cancer Network. 8 (3): 288–334. doi:10.6004/jnccn.2010.0021. PMID 20202462.
    • Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry (2001). "Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2". New England Journal of Medicine. 344 (11): 783–792. doi:10.1056/NEJM200103153441101. ISSN 0028-4793. PMID 11248153.
    • Howell, A. (2002). "Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment". Journal of Clinical Oncology. 20 (16): 3396–3403. doi:10.1200/JCO.2002.10.057. ISSN 0732-183X.
    • Lutz, Stephen; Berk, Lawrence; Chang, Eric; Chow, Edward; Hahn, Carol; Hoskin, Peter; Howell, David; Konski, Andre; Kachnic, Lisa; Lo, Simon; Sahgal, Arjun; Silverman, Larry; von Gunten, Charles; Mendel, Ehud; Vassil, Andrew; Bruner, Deborah Watkins; Hartsell, William (2011). "Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline". International Journal of Radiation Oncology*Biology*Physics. 79 (4): 965–976. doi:10.1016/j.ijrobp.2010.11.026. ISSN 0360-3016.
    • Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crinó, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Jänne, Pasi A. (2013). "Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer". New England Journal of Medicine. 368 (25): 2385–2394. doi:10.1056/NEJMoa1214886. ISSN 0028-4793. PMID 23724913. S2CID 19466284.
    • Sequist, L. V.; Yang, J. C.-H.; Yamamoto, N.; O'Byrne, K.; Hirsh, V.; Mok, T.; Geater, S. L.; Orlov, S.; Tsai, C.-M.; Boyer, M.; Su, W.-C.; Bennouna, J.; Kato, T.; Gorbunova, V.; Lee, K. H.; Shah, R.; Massey, D.; Zazulina, V.; Shahidi, M.; Schuler, M. (2013). "Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations". Journal of Clinical Oncology. 31 (27): 3327–3334. doi:10.1200/JCO.2012.44.2806. ISSN 0732-183X. PMID 23816960.
    • Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M.M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A. (2011). "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation". New England Journal of Medicine. 364 (26): 2507–2516. doi:10.1056/NEJMoa1103782. ISSN 0028-4793. PMID 21639808.
    • Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A. (2004). "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib" (PDF). New England Journal of Medicine. 350 (21): 2129–2139. doi:10.1056/NEJMoa040938. ISSN 0028-4793. PMID 15118073.
    • Keedy, V. L.; Temin, S.; Somerfield, M. R.; Beasley, M. B.; Johnson, D. H.; McShane, L. M.; Milton, D. T.; Strawn, J. R.; Wakelee, H. A.; Giaccone, G. (2011). "American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy". Journal of Clinical Oncology. 29 (15): 2121–2127. doi:10.1200/JCO.2010.31.8923. ISSN 0732-183X. PMID 21482992.
    • Allegra, C. J.; Jessup, J. M.; Somerfield, M. R.; Hamilton, S. R.; Hammond, E. H.; Hayes, D. F.; McAllister, P. K.; Morton, R. F.; et al. (2009). "American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy". Journal of Clinical Oncology. 27 (12): 2091–2096. doi:10.1200/JCO.2009.21.9170. ISSN 0732-183X. PMID 19188670.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Wikipedia:Choosing_Wisely/American_Society_of_Clinical_Oncology&oldid=1093937317"